Clinical Trial Update: An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

An open-label Phase 2 trial compares the combination of SLC-3010 with Axitinib versus Axitinib alone as second-line therapy for locally advanced or metastatic c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)
• SLC-3010

Snippet

Sponsor: Yonsei University | Conditions: Clear Cell Renal Cell Carcinoma, Neoplasms | Phase 2 | Status: RECRUITING